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A B S T R A C T
Hemolytic diseases are associated with elevated levels of circulating free heme that can mediate endothelial
dysfunction directly via redox reactions with biomolecules or indirectly by upregulating enzymatic sources of
reactive species. A key enzymatic source of these reactive species is the purine catabolizing enzyme, xanthine
oxidase (XO) as the oxidation of hypoxanthine to xanthine and subsequent oxidation of xanthine to uric acid
generates superoxide (O2•-) and hydrogen peroxide (H2O2). While XO has been studied for over 120 years, much
remains unknown regarding specific mechanistic roles for this enzyme in pathologic processes. This gap in
knowledge stems from several interrelated issues including: 1) lethality of global XO deletion and the absence of
tissue-specific XO knockout models have coalesced to relegate proof-of-principle experimentation to pharma-
cology; 2) XO is mobile and thus when upregulated locally can be secreted into the circulation and impact distal
vascular beds by high-affinity association to the glycocalyx on the endothelium; and 3) endothelial-bound XO is
significantly resistant (> 50%) to inhibition by allopurinol, the principle compound used for XO inhibition in
the clinic as well as the laboratory. While it is known that circulating XO is elevated in hemolytic diseases
including sickle cell, malaria and sepsis, little is understood regarding its role in these pathologies. As such, the
aim of this review is to define our current understanding regarding the effect of hemolysis (free heme) on
circulating XO levels as well as the subsequent impact of XO-derived oxidants in hemolytic disease processes.
1. Introduction
Excess circulating free heme is associated with numerous hemolytic
diseases including sickle cell disease (SCD), thalassemia, sepsis, cardiac
bypass, and malaria [1–5]. Oxidation of reduced heme (Fe2+ → Fe3+)
can result in heme and hemoglobin (Hb) release from red blood cells
(RBCs) into the circulation [2,6]. Under normal physiologic conditions,
heme and Hb are immediately scavenged and degraded in plasma or
sequestered and transported to tissues such as the liver for degradation
[2,6]. However, under conditions of severe hemolysis, circulating heme
reaches levels that saturate the scavenging and degradation pathways,
resulting in significant extracellular levels of free heme that can initiate
intravascular cell and tissue damage [2,6].
Under basal levels of hemolysis, Hb is bound by haptoglobin (Hp)
and targeted to macrophages where the complex is taken up via en-
docytosis and degraded (Fig. 1) [2]. Likewise, free heme in the plasma
is either bound by hemopexin (Hx) or immediately degraded to iron,
carbon monoxide and biliverdin by the enzyme heme oxygenase-1 (HO-
1) [1]. Hx targets heme primarily to the liver and spleen, allowing heme
to be cleared through the endothelium, endocytosed by hepatocytes and
degraded by cellular HO-1 or redistributed for heme iron recycling
(Fig. 1) [2,6]. However, under conditions of severe hemolysis, Hx and
HO-1 become saturated, resulting in oxidative damage to surrounding
tissues due to a decrease in heme degradation and simultaneous in-
crease in circulating free heme [2]. For example, reaction of free heme
with O2 can generate superoxide (O2•-), and subsequently elevate hy-
drogen peroxide (H2O2) levels via spontaneous or enzymatic dismuta-
tion as well as hydroxyl radical (HO•) levels by reaction of peroxide(s)
with transition metals including heme-iron (Fe). Enhanced abundance
of these reactive species mediate lipid, protein, and DNA oxidation
resulting in cell and tissue damage, endothelial dysfunction, and loss of
vascular homeostasis (Fig. 1) [1,7]. While the catalytically-active Fe in
heme as well as “free Fe” derived from heme is considered the seminal
source of oxidants in hemolytic disease, subsequent contributions from
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alternative sources are significant to the progression of this in-
flammatory process. For example, free heme activates toll-like receptor
4 (TLR4) signaling, resulting in activation of pro-inflammatory path-
ways which include amplification of ROS levels from sources alter-
native to those generated via Fe-mediated reactions (Fig. 1) [2,8].
In addition to hemolysis, reactive oxygen species (ROS) and reactive
nitrogen species (RNS) (e.g. nitric oxide (•NO), nitrogen dioxide (•NO2)
and peroxynitrite (ONOO-)) are generated under numerous pathological
conditions that often accompany hemolytic diseases (e.g. ischemia-re-
perfusion injury and chronic inflammation) [9–11]. The main pathways
in which O2•- is generated include the mitochondrial electron transport
chain, nicotinamide-adenine dinucleotide phosphate (NADPH) oxi-
dases, uncoupled nitric oxide synthase (NOS), and xanthine oxidase
(XO) [10]. XO is one such mechanism that is noted to be upregulated in
hemolytic disease [12]. XO generates oxidants by shuttling electrons
derived from purine oxidation to either univalently (O2•-) or divalently
(H2O2) reduce O2 [12]. This elevation of XO activity may result in in-
creased formation of RNS via the diffusion-limited reaction between
XO-derived O2•- with •NO to generate ONOO- [13]; however, increased
rates of O2•- formation from the other sources mentioned above may
also contribute. The increased presence of ONOO- may lead to altera-
tion in cell signaling via post-translational modification of critical
sulfhydryls on effector proteins, diminution of •NO-mediated vasodila-
tory action, and loss of endothelial barrier integrity via induction of
membrane lipid peroxidation [14,15].
2. Xanthine oxidase
Xanthine oxidoreductase (XOR) is a name commonly used to en-
compass two interconvertible forms of the same enzyme: dehy-
drogenase (XDH) and oxidase (XO) [16]. XOR is transcribed and
translated as XDH, a ~300 kDa homodimer consisting of four redox
centers in each subunit: one molybdenum cofactor (Mo-co), one flavin
adenine dinucleotide (FAD) site, and two Fe2S2 sites [17]. XDH cata-
lyzes the oxidation of hypoxanthine to xanthine and xanthine to uric
acid at the Mo-co site and electrons are shuttled via the two Fe2S2
clusters to the FAD site where NAD+ is reduced to NADH. XOR exists
primarily as XDH intracellularly; yet, once in the extracellular space
and circulation XO is the dominant isoform [17]. The principle differ-
ence between XO and XDH is their oxidizing substrate affinity where
XO demonstrates diminished affinity for NAD+and over 11-fold in-
creased affinity for O2 [18]. As such, electrons derived from hypox-
anthine and xanthine oxidation by XO are quickly accepted by O2 to
generate O2•- and H2O2 [12]. Della Corte and Stirpe made several im-
portant discoveries in the late 1960s and early 1970s showing that XOR
is irreversibly or reversibly converted to XO via proteolysis or oxidation
of cysteine residues, respectively [19–21]. As the crystal structure of
bovine milk XDH was solved, the site of proteolysis was identified as
following Lys551 and the sites of oxidation were identified as Cys535
and Cys592 with formation of a disulfide bridge [18].
Fig. 1. A red blood cell (RBC) undergoing he-
molysis releases hemoglobin (Hb) and heme.
Hb is bound by haptoglobin (Hp) and targeted
to macrophages for degradation. Heme is ei-
ther 1) bound by hemopexin (Hx) and targeted
to the liver for iron storage, redistribution, or
degradation by cellular heme oxygenase-1
(HO-1); or 2) degraded directly in the plasma
by HO-1 into iron, carbon monoxide (CO) and
biliverdin (gray panel). Hemolytic diseases
cause elevated levels of hemolysis which satu-
rate Hx and HO-1. When these pathways are
saturated, heme activates toll-like receptor-4
(TLR4) triggering an immune response.
Separately, heme can also generate reactive
oxygen species (ROS) directly and indirectly
through iron (green panel).
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3. XOR regulation
While much is known regarding XOR biochemistry, transcriptional
and translational regulation is much less understood. The human xdh
gene is located on the p22 band of chromosome two and contains
several possible binding sites for translational modification: four
CCAAT/enhancer binding sites, three IL-6 responsive elements, an NF-
κB site, and TNFα, interferon-γ, and interleukin-1 responsive units [22].
XOR expression is reported to be controlled by a variety of factors in-
cluding hormones, growth factors, and inflammatory cytokines; yet, the
most studied effector of XOR expression/activity is hypoxia [23,24].
While many studies have described transcriptional and post-transla-
tional up-regulation of XOR by severe hypoxia [25–28], modest hy-
poxia (10% O2) is also capable of inducing significant elevation of XOR
expression, activity, export from endothelial cells, and XO-dependent
ROS production [24]. The described moderate hypoxic conditions are
comparable to levels observed in congestive heart failure patients [24].
Parks and Granger were the first to describe an elevation in purine
catabolites under hypoxic conditions as they attributed the increased
hypoxanthine observed during hypoxia to the breakdown of AT-
P→ADP→AMP→adenosine→inosine→hypoxanthine (purine degrada-
tion pathway) [29]. This is crucial in terms of XO function as increased
levels of hypoxanthine require increased XO activity for further oxi-
dation to uric acid, all while generating O2•- and H2O2 as byproducts
[29]. It is important to note that elevated circulating free heme can
induce RBC lysis resulting in release of ATP into the circulation
[30–32]. This ATP is quickly catabolized to adenosine then to hypox-
anthine creating a milieu similar to that described above for moderate
hypoxia [30]. Elevated levels of hypoxanthine may consequently
trigger upregulation of XOR activity in addition to activating purine
salvage via hypoxanthine-guanine phosphoribosyltransferase (HPGRT)
[33]. Interestingly, we have previously described upregulation of XOR
via adenosine activation of adenosine A2B receptors on endothelial cells
[24]. Therefore, the combination of increased adenosine and hypox-
anthine levels could significantly amplify XOR activity and allied ROS
generation during hemolytic crisis; a process already wrought with
abundant oxidant generation attributable to heme itself.
4. XOR-endothelial interaction
A critical concept when considering the impact of XOR on disease
processes in general and hemolytic disease specifically, is that XOR is
mobile and has a high affinity (Kd =6nM) for glycosaminoglycans
(GAGs) on the apical surface of the vascular endothelium [34,35]. As
such, XOR can be upregulated in one anatomic site (e.g. liver), exported
to the circulation, bound to endothelial GAGs and thus sequestered in
vascular beds distal from the site of origin [34–38]. When coupled to
the elevated circulating levels of hypoxanthine, it is in this setting that
XO can critically contribute to oxidant-mediated vascular dysfunction
[39]. Binding and immobilization of XOR on the vascular GAGs also has
significant kinetic consequences including alteration in the relative
amounts of O2•- and H2O2 produced as well as resistance to inhibition
by pyrazolopyrimidine-based inhibitors (see Therapeutic Inhibitors of
XO, below) [40–42]. In the aggregate, mobility and capacity to avidly
associate to the endothelium in a manner that is resistant to inhibition
affords XO the ability to critically contribute to loss of vascular
homeostasis.
5. Therapeutic inhibitors of XO
There are currently two XO inhibitors that are FDA approved for the
treatment of gout: allopurinol and febuxostat [43]. While allopurinol
has been used in the clinic for over fifty years, febuxostat (Uloric®) was
approved in 2009 [43]. Current reports suggest allopurinol may be the
superior drug for diminishing uric acid levels to the extent that symp-
toms of gout are alleviated; however, febuxostat is a more potent XO
inhibitor and may be more useful in treating diseases with elevated XO
activity at the surface of endothelial cells [43]. Allopurinol is a hy-
poxanthine mimetic that prevents oxidation of hypoxanthine and xan-
thine at the Mo-co site of XOR [44]. XOR oxidizes allopurinol, a suicide
inhibitor, with the transfer of two electrons to form oxypurinol, the
pharmacologically active form of the drug, which then competitively
inhibits XO [40,45]. Since the oxidation of allopurinol to oxypurinol
results in reduction of XOR, O2•- and H2O2 are generated as unfortunate
byproducts [40]. In addition, GAG-immobilized XOR is resistant to in-
hibition by allo/oxypurinol. For example, concentrations (200–400 µM)
of allo/oxypurinol, greater than the clinical working range (20–80 µM)
are required to achieve 45–50% inhibition of XO [41]. While allopur-
inol is effective at relieving symptoms of gout, it may be a poor choice
for targeting endothelial-associated XO-derived ROS generation.
Febuxostat is reported to have a Ki some 6000 times lower than
allopurinol and does not react directly with the Mo-co site of XOR, but
rather binds the pocket leading to the active site via electrostatic in-
teraction thus blocking purine access. As such, it does not induce en-
zyme turn-over and unwanted production of O2•- and H2O2 [40,46,47].
This makes febuxostat an ideal pharmaceutic for pathologic conditions
where O2•- and H2O2 generated by XO contribute to endothelial injury.
The IC50 of febuxostat (4.4 nM) did increase 2.5-fold when XO was
bound by GAGs, but this is significantly lower than the 22-fold increase
observed with allopurinol (64 μM) [40]. Febuxostat completely in-
hibited O2-• formation at or below 50 nM, a concentration well below
the clinical Cmax (15 μM) [40].
Whereas both pyrazolopyrimidine-based inhibitors and febuxostat
are effective in reducing uric acid levels and oxidant generation by
inhibiting XO, they are not without shortcomings. For example, clinical
administration of allopurinol: 1) is limited to significantly reduced
dosing in patients with preexisting renal disease, 2) is known to mediate
substantive hypersensitivity issues which also limits dosage and 3) ef-
fects alternative purine catabolic pathways [15,48]. While febuxostat
has demonstrated superior specificity and potency to allo/oxypurinol, it
too has been associated with negative clinical outcomes. For example,
febuxostat administration has been associated with rhabdomyolysis in
patients with chronic kidney disease (CKD) [49] and has been shown to
be non-inferior to allopurinol regarding rates of adverse cardiovascular
events where all-cause mortality and cardiovascular mortality were
greater in febuxostat-treated patients than patients treated with allo-
purinol [50]. When taken together, the issues related to currently
available FDA-approved XO inhibition approaches may indeed limit the
potential for their effective use in hemolytic disease, affirming the need
for alternative approaches to alter XO activity.
6. XOR, ROS and hemolytic diseases
Upregulation of XDH has been associated with hypoxia-induced
vaso-occlusive crisis in SCD mice and humans [12,51]. Aslan and col-
leagues demonstrated that ischemia/reperfusion injury in SCD mice
resulted in release of XDH from the liver into the circulation, rapid
conversion to XO via plasma proteases, immobilization on endothelial
GAGs, and represented a major source of O2•- and H2O2 in the vascular
compartment [12], as depicted in Fig. 2. In this setting, XO-derived
oxidants can alter cell signaling processes as well as induce overt da-
mage [12]. For example, diminution in •NO-mediated signaling (e.g.
vasodilatory response) can result from the diffusion-limited reaction
between XO-derived O2•- and •NO to form O=NOO-. In addition, both
XO-derived O2•- and H2O2 can mediate protein and lipid oxidation
which can affect vascular homeostasis by also altering signaling path-
ways directly (e.g. oxidation of eNOS-associated BH4) or indirectly via
disruption of cellular membrane integrity. Evidence for the contribu-
tion of XO to oxidant load is also revealed by substantively elevated
circulating XO in SCD patients compared to healthy controls [51].
Hepatic ischemic injury and hypoxia, in mice and rats, also increase
XDH release from the liver into the vasculature and induce rapid
H.M. Schmidt et al. Redox Biology 21 (2019) 101072
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conversion of XDH to XO during reperfusion [52,53]. Due to the rela-
tively high circulating half-life of XO, significant damage can be done to
the endothelium due to XO-dependent oxidant generation [52]. Ele-
vated XO levels were observed in diseases involving liver injury such as
hepatitis, jaundice, and chronic renal failure (secondary effects on the
liver) [52]. Of particular interest is that elevated levels of circulating
XO are reported to positively associate with chronic liver disease (cir-
rhosis, chronic hepatitis and cholestatic disorders); yet, they do not
correlate with indices of liver damage, suggesting a signaling event
alternative to hepatocellular damage is operative, and thus may drive
upregulation of XDH with subsequent release into the circulation [54].
However, patients with virus-related cirrhosis demonstrated sig-
nificantly enhanced levels of circulating XO that did positively correlate
with the extent of liver damage as indicated by assessment of ALT
leaving the field a bit unclear at present [55].
More specifically related to “hemolytic” disease are patients with
malaria and/or sepsis. Asymptomatic malaria patients demonstrate a
two-fold elevation in circulating XO levels compared to controls
whereas patients hospitalized with severe malaria have plasma XO le-
vels over 3.25-fold greater than asymptomatic individuals and thus 6.5-
fold greater than controls [4]. Similarly, upon diagnosis, sepsis patients
who did not subsequently survive presented with significantly elevated
plasma (2.2-fold) XO activity [5]. However, 24 h post diagnosis these
non-survivors displayed less plasma XO activity than survivors; thus,
indicating a temporal relationship regarding circulating XO activity and
the severity of the disease as well as the overall outcome. Regardless of
survival outcomes, plasma XO activity correlated positively with in-
dices of oxidant stress including protein carbonylation and lipid per-
oxidation. This principle was also seen in a rodent model of experi-
mental sepsis where treatment with allopurinol and/or metal chelation
therapy with desferrioxamine significantly abrogated the abundance of
biomolecular free radicals indicating critical contributions from both
XO and Fenton-type reactions stemming from RBC lysis [56].
While it is clear that there are contributory roles for XO in hemolytic
disease, it is equally clear that the mechanisms underpinning specific
signaling events leading to upregulation of XDH, triggers to release
XDH into the circulation and the subsequent impact of circulating XO
remain to be defined. For example, it has been suggested that TLR-4
signaling serves to elevate XOR levels [57]; yet, there are no reports
revealing empirical evidence that this is the case. On the other hand, it
has been reported that XO-derived ROS were essential for TLR4-in-
duced NFAT5 (nuclear factor of activated T cells) activation of murine
macrophages; again, leaving the field a bit unclear [58]. This gap in our
current understanding of the linkage between heme overload and up-
regulation of XDH affirms the need for further study.
Hx is a natural antioxidant that binds heme as it is released during
hemolysis and targets the complex to the liver parenchymal cells for
degradation and recycling of the Hx and iron [59]. However, increased
nitration of Hx during inflammation can diminish the protective anti-
oxidant properties during heme toxicity [59]. Erythrocytes undergo a
significant amount of oxidative stress and ROS production and thus
require a number of enzymatic and non-enzymatic antioxidants in-
cluding superoxide dismutase (SOD), catalase (CAT), glutathione per-
oxidase (GPx), glutathione reductase (GR), glutathione (GSH) and vi-
tamins E and C [60]. SCD hemoglobin generates twice as much O2-•,
H2O2 and HO• compared to normal hemoglobin, and thus have in-
creased antioxidant function often resulting in antioxidant deficiencies
[60]. Antioxidant therapeutic approaches are being examined as an
option for treating SCD because they can be administered at low cost
through food and can be administered in combination with hydro-
xyurea to decrease oxidative stress [61].
7. Summary and conclusions
The high levels of hemolysis associated with hemolytic diseases,
cause a saturation of protective pathways resulting in an increase in O2•-
, H2O2 and •HO generation and activation of inflammatory pathways
[2,8]. XO is one mechanism of ROS generation that has been observed
Fig. 2. Xanthine oxidase (XO) released from
the liver can bind to the surface of endothelial
cells via interactions with glycosaminoglycans
(GAGs). As hypoxanthine is converted to xan-
thine, and xanthine to uric acid by XO, reactive
oxygen species (ROS) are generated at the
surface of endothelial cells. XO produces either
O2•- or H2O2 which can lead to production of
ONOO- or •HO (top). Treatment with an XO
inhibitor such as febuxostat inhibits XO and
blocks the conversion of hypoxanthine to xan-
thine and xanthine to uric acid preventing ROS
production and damage at the endothelial cell
surface (bottom).
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in elevated circulating levels in murine models of hemolytic disease and
clinically. Circulating XO can significantly contribute to the oxidant
load in the vascular compartment by binding to the endothelial gly-
cocalyx [34,35]. In this setting XO is resistant to inhibition by clinically
applicable concentrations of allo/oxypurinol and thus may serve to
amplify the oxidant load derived from heme-related reactions and thus
exacerbate an existing oxidant assault. However, the signaling events
that link elevation in heme concentration and upregulation/export of
cellular XDH are not defined. Further exploration of these signaling
events will provide a clearer understanding of the role of XOR in he-
molytic disease and likely improve clinical practices and outcomes.
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